Hepatitis B and Delta in Peru: Current Status and Control
Descripción del Articulo
Hepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate en...
Autores: | , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2018 |
Institución: | Colegio Médico del Perú |
Repositorio: | Acta Médica Peruana |
Lenguaje: | español |
OAI Identifier: | oai:amp.cmp.org.pe:article/2631 |
Enlace del recurso: | https://amp.cmp.org.pe/index.php/AMP/article/view/2631 |
Nivel de acceso: | acceso abierto |
Materia: | hepatitis B/epidemiología transmisión prevención & control Hepatitis D/epidemiología Perú hepatitis B / epidemiology transmission prevention & control hepatitis D / epidemiology Peru |
id |
REVCMP_3d7e26c3373c2b03a545ea29dedb45d6 |
---|---|
oai_identifier_str |
oai:amp.cmp.org.pe:article/2631 |
network_acronym_str |
REVCMP |
network_name_str |
Acta Médica Peruana |
repository_id_str |
. |
spelling |
Hepatitis B and Delta in Peru: Current Status and ControlSituación y control de la hepatitis B y Delta en el PerúCabezas Sánchez, Cabezas SánchezCabezas Sánchez, Césarhepatitis B/epidemiologíatransmisiónprevención & controlHepatitis D/epidemiologíaPerúhepatitis B / epidemiologytransmissionprevention & controlhepatitis D / epidemiologyPeruHepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate endemicity, although there are areas with high, medium and low endemicity; however, migration is spreading these infections. It is important to point out that there is horizontal transmission in children from endemic areas and a low level of vertical transmission, which is an advantage in order to achieve early protection using the hepatitis B vaccine. This vaccine HBV is efficacious and safe, and vaccination is still one of the most cost-effective interventions. Pilot hepatitis B vaccination programs have been implemented in Peru, achieving a significant impact on the infection rates; so it is advisable to expand the target population, particularly teenagers and other risk groups, so that the time period to eliminate hepatitis B infection may be shortened, as well as its chronic sequels. There have been some advances in prevention, but we still have to take care of chronic carriers. Knowing that there are therapy strategies available for subjects positive and negative for HBeAg, it is advisable to propose therapy programs and to assess all interventions performed. These are the topics included in this review.El virus de la hepatitis B es un virus DNA altamente infeccioso cuyo estado de portador crónico conlleva a la cirrosis y el cáncer de hígado y esto se da en plazos mas cortos si está asociado al virus D como ocurre en el Perú. Nuestro país tiene en promedio una endemicidad intermedia, aunque hay áreas de alta, mediada y baja endemicidad; sin embargo la migración de personas entre estas áreas, está dispersando la infección. Debe destacarse en el pais la transmisión horizontal en niños de áreas endémicas y la baja transmisión vertical, lo que es una ventaja para proteger tempranamente con la vacuna. La vacuna disponible contra HBV es eficaz y segura, y siendo la vacunación una de las intervenciones más costo efectivas, se han desarrollado programas de vacunación piloto en el país, con un significativo impacto sobre la tasa de infección; por lo que amerita ampliar la población objetivo a inmunizar, como son los adolescentes y jóvenes y grupos de riesgo de manera que se acorten los periodos para eliminar la infección por HBV y por tanto sus secuelas crónicas. Hay avances en la prevención, pero aun queda que hacer con los portadores crónicos. Habiendo perspectivas terapéuticas tanto para los HBeAg positivos y HBeAg negativos, será pertinente plantear programas de tratamiento y de otro lado evaluar todas las intervenciones efectuadas. Estos son los temas que se incluyen en esta revisión.Colegio Médico del Perú2018-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/2631ACTA MEDICA PERUANA; Vol. 25 No. 2 (2008); 96-112ACTA MEDICA PERUANA; Vol. 25 Núm. 2 (2008); 96-1121728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/2631/1528Copyright (c) 2023 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/26312023-07-06T05:52:20Z |
dc.title.none.fl_str_mv |
Hepatitis B and Delta in Peru: Current Status and Control Situación y control de la hepatitis B y Delta en el Perú |
title |
Hepatitis B and Delta in Peru: Current Status and Control |
spellingShingle |
Hepatitis B and Delta in Peru: Current Status and Control Cabezas Sánchez, Cabezas Sánchez hepatitis B/epidemiología transmisión prevención & control Hepatitis D/epidemiología Perú hepatitis B / epidemiology transmission prevention & control hepatitis D / epidemiology Peru |
title_short |
Hepatitis B and Delta in Peru: Current Status and Control |
title_full |
Hepatitis B and Delta in Peru: Current Status and Control |
title_fullStr |
Hepatitis B and Delta in Peru: Current Status and Control |
title_full_unstemmed |
Hepatitis B and Delta in Peru: Current Status and Control |
title_sort |
Hepatitis B and Delta in Peru: Current Status and Control |
dc.creator.none.fl_str_mv |
Cabezas Sánchez, Cabezas Sánchez Cabezas Sánchez, César |
author |
Cabezas Sánchez, Cabezas Sánchez |
author_facet |
Cabezas Sánchez, Cabezas Sánchez Cabezas Sánchez, César |
author_role |
author |
author2 |
Cabezas Sánchez, César |
author2_role |
author |
dc.subject.none.fl_str_mv |
hepatitis B/epidemiología transmisión prevención & control Hepatitis D/epidemiología Perú hepatitis B / epidemiology transmission prevention & control hepatitis D / epidemiology Peru |
topic |
hepatitis B/epidemiología transmisión prevención & control Hepatitis D/epidemiología Perú hepatitis B / epidemiology transmission prevention & control hepatitis D / epidemiology Peru |
description |
Hepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate endemicity, although there are areas with high, medium and low endemicity; however, migration is spreading these infections. It is important to point out that there is horizontal transmission in children from endemic areas and a low level of vertical transmission, which is an advantage in order to achieve early protection using the hepatitis B vaccine. This vaccine HBV is efficacious and safe, and vaccination is still one of the most cost-effective interventions. Pilot hepatitis B vaccination programs have been implemented in Peru, achieving a significant impact on the infection rates; so it is advisable to expand the target population, particularly teenagers and other risk groups, so that the time period to eliminate hepatitis B infection may be shortened, as well as its chronic sequels. There have been some advances in prevention, but we still have to take care of chronic carriers. Knowing that there are therapy strategies available for subjects positive and negative for HBeAg, it is advisable to propose therapy programs and to assess all interventions performed. These are the topics included in this review. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-06-30 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2631 |
url |
https://amp.cmp.org.pe/index.php/AMP/article/view/2631 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2631/1528 |
dc.rights.none.fl_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Colegio Médico del Perú |
publisher.none.fl_str_mv |
Colegio Médico del Perú |
dc.source.none.fl_str_mv |
ACTA MEDICA PERUANA; Vol. 25 No. 2 (2008); 96-112 ACTA MEDICA PERUANA; Vol. 25 Núm. 2 (2008); 96-112 1728-5917 1018-8800 reponame:Acta Médica Peruana instname:Colegio Médico del Perú instacron:CMP |
instname_str |
Colegio Médico del Perú |
instacron_str |
CMP |
institution |
CMP |
reponame_str |
Acta Médica Peruana |
collection |
Acta Médica Peruana |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1842710633334702080 |
score |
12.8608675 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).